Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
20 March 2018 Photo Charl Devenish
Town and Gown programme to expand university reach in communities
Prof Petersen signs an MOU with Princess Motshabi Moroka, patron of the Princess Gabo Foundation, at the launch of the Town and Gown programme.
The University of the Free State (UFS), through the office of Community Engagement, launched the Town and Gown programme on 13 March 2018 at the Bloemfontein Campus. The programme seeks to demonstrate the university’s commitment to building sustainable partnerships in communities and its surrounding towns. It aims to be integrally involved in addressing societal challenges, as well as to avail its intellectual and academic resources to partner with civic and religious organisations, government entities and business communities.

Engaged scholarship central to institutional strategy
In his welcoming remarks, Prof Nicky Morgan Acting Vice Rector: Institutional Change and Student Affairs, said: “The university is not complete without its community and in the same way the community should benefit from the university. This has been encompassed in the newly launched Integrated Transformation Plan (ITP) which has community engagement as one of its components.”  The event was attended by representatives of the Mangaung Metropolitan Municipality, NGOs, religious and traditional leaders, student structures and UFS staff members.

Prof Francis Petersen: Rector and Vice Chancellor, said the university ought to articulate community engagement differently from what other organisations would do, by showcasing engaged scholarship and using teaching and research to make a difference. He emphasised the importance of being close enough to communities to be able to ascertain their needs in such a way that the component of community is brought into the classroom and in the university’s research.

Expansion of community outreach under way
The long-standing ties between the university and communities in the Free State span many years, during which time various collaborative projects have been established with, among others, Non Profit Organisations (NPOs), such as Bloemshelter, faith-based organisations, and traditional leadership structures.

To date, the UFS has supported programmes in education, health, law and rural development through service-learning programmes, involving students and academics in various fields. The target of the Town and Gown programme is to reach out further to include new partnerships in the Motheo Metro Municipality, Maluti-a-Phofung District Municipality, and Kopanong Local Municipality.

Long-standing partnerships strengthened
At the event, several memoranda of understanding (MOU) were signed to confirm five-year collaborative agreements between the university and partner organisations, one of which is the Princess Gabo Foundation based in Thaba Nchu. Bishop Billyboy Ramahlele, Director: Community Engagement said that the MOUs would strengthen partnership with the communities in research, community service learning, and volunteer programmes.

The Town and Gown initiative is a step taken to re-affirm the university’s commitment to partnering with stakeholders in strengthening the capacity of surrounding towns, metros and the Free State region as a whole.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept